Open-label, Dose Ascending Safety, Tolerability, and Proof of Concept Study to Evaluate the Use of ANXV (Human Recombinant Annexin A5) in the Treatment of Subjects With Recently Diagnosed Retinal Vein Occlusion
Open-label, dose ascending safety, tolerability, and proof of concept study to evaluate the use of ANXV (human recombinant Annexin A5) in the treatment of subjects with recently diagnosed Retinal Vein Occlusion.
100 Clinical Results associated with Infocus Clinical Research LLC
0 Patents (Medical) associated with Infocus Clinical Research LLC
100 Deals associated with Infocus Clinical Research LLC
100 Translational Medicine associated with Infocus Clinical Research LLC